The potential impact of the use of homeopathic and herbal remedies on monitoring the safety of prescription products

Human and Experimental Toxicology

Volumn 24, Issue 5, 2005, Pages 219-233

  Woodward, K N ^a,b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b Schering Plough Animal Health   (United Kingdom)

Author keywords

Adverse reactions; Herbal; Homeopathic; Pharmacovigilance; Regulatory

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIGOUT AGENT; ANTINEOPLASTIC AGENT; ARSENIC; BETAMETHASONE; BROMATE; CARDIOTONIC AGENT; COLCHICINE; CONVENTIONAL DRUG; DIAZEPAM; DICLOFENAC; DIGITALIS PURPUREA; DIGOXIN; DRUG; ECHINACEA EXTRACT; EPHEDRA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HEAVY METAL; HERBACEOUS AGENT; HOMEOPATHIC AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; MORPHINE; QUININE; SABAL EXTRACT; SENNOSIDE; THALLIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; VINCRISTINE;

ABORTION; ALTERNATIVE MEDICINE; ANAPHYLAXIS; AWARENESS; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRUISING; CARDIOTOXICITY; CATHARANTHUS ROSEUS; CINCHONA; CINCHONA LEDGERIANA; COLCHICUM; COLCHICUM AUTUMNALE; CONFUSION; CONTACT DERMATITIS; DIARRHEA; DIGITALIS LANATA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDEMA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPHEMA; HYPOGLYCEMIA; HYPOKALEMIC PERIODIC PARALYSIS; HYPOMANIA; INTERMITTENT CLAUDICATION; KIDNEY INJURY; LETHARGY; LIBIDO DISORDER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; MANIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVARY INSUFFICIENCY; PAPAVER; PAPAVER SATIVUM; PEMPHIGOID; PHOTOSENSITIVITY DISORDER; PLANT; POISON IVY; POSTOPERATIVE HEMORRHAGE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SELF MEDICATION; SENNA; SHOCK; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TACHYCARDIA; TERATOGENICITY; TORSADE DES POINTES; URINE RETENTION; VAGINA BLEEDING; VOMITING;

EUROPE; HERB-DRUG INTERACTIONS; HUMANS; LEGISLATION, DRUG; MATERIA MEDICA; PLANT PREPARATIONS; UNITED STATES;

EID: 21744459866     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327105ht529oa     Document Type: Review

References (310)

1. Griffin JP, Weber JCP. Voluntary systems of adverse drug reporting. Part I. Adverse drug reaction reporting. Acute Poisoning Rev 1985; 4: 213-30.
2. Griffin JP. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986; 22: 83S-100S
3. Rawlins MD. Spontaneous reporting of adverse drug reactions I: uses. Br J Clin Pharmacol 1988; 26: 7-11.
4. Hornbuckle K, Wu H-H, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter - a 15-year review (1983-1997). Drug Inf J 1999; 33: 1117-24.
5. Amery WK. Signal generation from spontaneous adverse event reports. Pharmacoepidemiol Drug Saf 1999; 8; 147-50.
6. Hasford J, Goettler M, Munter K-H, Müller-Oerlinghausen B. Physicians knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945-50.
7. Kennedy DL, Goldman SA, Little RB. Spontaneous reporting in the United States. In Strom BL ed. Pharmacoepidemiology. Chichester: Wiley, 2000: 151-74.
8. Routledge PA. Adverse drug reactions and interactions: Mechanisms, risk factor, detection, management and avoidance. In Stephens MBD, Talbot JCC, Routledge PA eds. Detection of new adverse drug reactions. London: Macmillan, 1999: 59-86.
9. Hartmann K, Koller Doser A, Kuhn M. Postmarketing safety information: how useful are spontaneous reports? Pharmacoepidemiol Drug Saf 1999; 8: S65-71.
10. van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 205-10.
11. Backstrom M, Mjorndal T, Dahlqvist R. Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf 2002; 11: 647-50.
12. Fontanarasa PB, Lundberg GD. Alternative medicines meets science. JAMA 1998; 280: 1618-19.
13. Ness J, Sherman FT, Pan CX. Alternative medicine: what the data say about common herbal therapies. Geriatrics 1999; 54: 33-38.
14. Farah MH, Edwards R, Lindquist M, Leon C, Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf 2000; 9: 105-12.
15. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States 1990-1997; results of a follow-up national survey. JAMA 1998; 280: 1569-75.
16. Koretz RL. Is alternative medicine alternative science? J Lab Clin Med 2002; 139: 329-33.
17. Shenfield G, Lim E, Allan H. Survey of the use of complementary medicines and therapies in children with asthma. J Paediatr Child Health 2002; 38: 252-57.
18. Linde K, Willich SN. How objective are systematic reviews? Differences between reviews on complementary medicine. J R Soc Med 2003; 96: 17-22.
19. Avina RL, Scheiderman LJ. Why patients choose homeopathy. West J Med 1978; 128: 366-69.
20. Brue AW, Oakland TD. Alternative treatments for attention-deficit/ hyperactivity disorder: does evidence support their use? Altern Ther Health Med 2002; 8: 68-70.
21. O'Meara S, Wilson P, Bridle C, Wright K, Kleijnen J. Homeopathy. Qual Saf Health Care 2002; 11: 189-94.
22. Ernst, E. A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol 2002; 54: 577-82.
23. Gee BC, Wilson P, Morris AD, Emerson RM. Herbal is not synonymous with safe. Arch Dermatol 2002; 138: 1613.
24. Capasso R, Izzo AA, Pinto L, Bifulco T, Vitobello, Mascolo N. Phytotherapy and quality of herbal medicines. Fitoterapia 2000; 71: S58-65.
25. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999; 56: 125-40.
26. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001; 135: 594-600.
27. Barrett B, Kiefer D, Rabago D. Assessing the risks and benefits of herbal medicine. An overview of scientific evidence. Altern Ther Health Med 1999; 5: 40-49.
28. Cohen MH. Regulation, religious experience, and epilepsy: a lens on complementary therapies. Epilepsy Behav 2003; 4: 602-606.
29. Topliss JG, Clark AM, Ernst E, Hufford CD, Johnson GAR, Rimoldi JM, Weimann BJ. Natural and synthetic substances related to human health. IUPAC Technical Report. Pure Appl Chem 2002; 74: 1957-85.
30. Zini A, Fishcher MA, Nam RK, Jarvi K. Use of alternative and hormonal therapies in male infertility. Urology 2004; 63: 141-43.
31. Weier KM, Beal MW. Complementary therapies as adjuncts in the treatment of postpartum depression. J Midwifery Womens Health 2004; 49: 96-104.
32. Van Wassenhoven M, Ives G. An observational study of patients receiving homeopathic treatment. Homeopathy 2004; 93: 2-11.
33. Brunelli B, Gorson KC. The use of complementary and alternative medicines by patients with peripheral neuropathy. J Neurol Sci 2004; 218: 59-66.
34. Sharples FMC, van Haselen R, Fisher P. NHS patients' perspective on complementary medicine: a survey. Complement Ther Med 2003; 11: 243-48.
35. Smith JR, Spurrier NJ, Travis Martin J, Rosenbaum JT. Prevalent use of complementary and alternative medicine by patients with inflammatory eye disease. Ocul Immunol Inflamm 2004; 12: 203-14.
36. Adusumilli PS, Ben-Porat L, Pereira M, Roesler D, Leitman IJ. The prevalence and predictors of herbal medicine use in surgical patients. J Am Coll Surg 2004; 198: 583-90.
37. Martin-Facklam M, Rieger K, Riedel K-D, Burhenne J, Walter-Sack I, Haefeli WE. Undeclared exposure to St. John's wort in hospitalized patients. Br J Clin Pharmacol 2004; 58: 437-41.
38. Trapskin P, Smith KM. Herbal medications in the perioperative orthopaedic surgery patient. Orthopedics 2004; 27: 819-22.
39. Kuo GM, Hawley ST, Weis LT, Balkrishnan V. Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. BMC Complement Altern Med 2004; 4: 18.
40. Cheng, J, Lee P, Li J, Dennehy CE, Tsourounis C. Use of Chinese herbal products in Oakland and San Francisco Chinatowns. Am J Health Syst Pharm 2004; 61: 688-94.
41. Yoon SL, Home CH, Adams C. Herbal product use by African American older women. Clin Nurs Res 2004; 13: 271-88.
42. Al-Windi A, Elmsfeldt D, Svärdsudd K. Determinants of drug utilisation in a Swedish municipality. Pharmacoepidemiol Drug Saf 2004; 13: 97-103.
43. Gözüm S, Ünsal A. Use of herbal therapies by older, community-dwelling women. J Adv Nurs 2004; 46: 171-78.
44. Aziz Z. Herbal medicines: predictors of recommendation by physicians. J Clin Pharm Ther 2004; 29: 241-46.
45. Slade K, Chohan BPS, Barker PJ. Evaluation of a GP practice based homeopathy service. Homeopathy 2004; 93: 67-70.
46. Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health 2004; 26: 152-57.
47. Schuppan D, Jia J-D, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-104.
48. Brevoort P. The booming US botanical market - an overview. Herbalgram 1996; 36: 49-57.
49. Johnston BA. One third of nation's adults use herbal remedies: market estimated at 3.24 billion. Herbalgram 1997; 40: 49.
50. Ambrose ET, Samuels S. Perception and use of herbals among students and their practitioners in a university setting. J Am Acad Nurse Pract 2004; 16: 166-73.
51. Tesch BJ. Herbs commonly used by women: an evidence based review. Am J Obstet Gynecol 2003; 188: S44-55.
52. Yu SM, Huang ZJ. Herbal supplement use among US women, 2000. J Am Womens Med Assoc 2004; 59: 17-24.
53. Anonymous. Program profile. International liaison brings global vision to OAM. Complement Altern Med NIH 1996; 3: 3.
54. Vaabengaard P, Clausen LM. Surgery patients' intake of herbal preparations and dietary supplements. Ugeskr Laeger 2003; 165: 3320-23.
55. Cassidy A. Are herbal remedies and dietary supplements safe and effective for breast cancer patients? Breast Cancer Res 2003; 5: 300-302.
56. Mills E, Ernst E, Singh R, Ross C, Wilson K. Health food store recommendations: implications for breast cancer patients. Breast Cancer Res 2003; 5: 170-74.
57. Block KI, Gyllenhaal C. Clinical corner: herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolising enzymes. Integr Cancer Ther 2002; 1: 83-89.
58. Pharand C, Ackman ML, Jackevicius CA, Paradisio-Hardy FL, Pearson GJ. Use of OTC herbal products with cardiovascular disease. Ann Pharmacother 2003; 37: 899-904.
59. Mendoza CE, Ferreira AC, de Machena E. Warfarin and herbal products interaction causing prosthetic aortic valve thrombosis presenting as myocardial infarction. J Heart Valve Dis 2004; 13: 22-24.
60. Ng TP, Tan CH, Kua EH. The use of Chinese herbal medicines and their correlate in Chinese older adults: the Singapore Longitudinal Aging Study. Age Ageing 2004; 33: 135-42.
61. Williamson AT, Fletcher PC, Dawson KA. Complementary and alternative medicine. Use in an older population. J Gerontol Nurs 2003; 29: 20-28.
62. Werneke U, Earl J, Seydel C, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90: 408-13.
63. D'Ambrosia R, Kilpatrick JA. Unknown risks of herbal medication use. Orthopedics 2004; 27: 803.
64. De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995; 13: 81-93.
65. Barret B, Kiefer D, Rabago D. Assessing the risks and benefits of herbal medicines: an overview of scientific evidence. Altern Ther Health Med 1999; 5: 40-49.
66. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 2001; 61: 2163-75.
67. Giese LA, Smith JJ. What is homeopathy? Gastroenterol Nurs 2002; 25: 67-69.
68. Ives G. The Blackie Memorial Lecture 1999. Homeopathy versus orthodoxy - the current state of play. Br Homeopath J 2000; 89: 17-25.
69. Vickers A, Zollman C. ABC of complementary medicine. Homeopathy. Br Med J 1999; 319: 1115-18.
70. Ballard R. Homeopathy. An overview. Aust Fam Physician 2000; 29: 1145-48.
71. Torres JL. Homeopathic effect: a network perspective. Homeopathy 2002; 91: 89-94.
72. Vockeroth WG. Veterinary homeopathy: an overview. Can Vet J 1999; 40: 592-594 and references therein.
73. Feder G, Katz T. Randomised clinical trials for homeopathy. Who wants to know the results? Br Med J 2002; 324: 498-99.
74. Jacobs J. Homeopathy should be integrated into mainstream medicine. Altern Ther Health Med 1995; 1: 48.
75. Sampson W. Homeopathy does not work. Altern Ther Health Med 2002; 1: 48-53.
76. Ernst E. Homeopathy: inaccuracies, misunderstandings and half-truths in allopathic doses. Clin Oncol 2002; 14: 254-55.
77. Aulas J-J. Is the evidence for homeopathy reproducible? Lancet 1995; 345: 251.
78. Reilly D, Taylor MA, Beattie NGM, Campbell JH, McSharry C, Aitchison TC, Carter R, Stevenson RD. Is evidence for homeopathy reproducible? Lancet 1994; 344: 1601-606.
79. Thomas WE. Homeopathy. Aust Fam Physician 2001; 30: 97-98.
80. Paterson ICM. Homeopathy: what is it and is it of value in the care of patients with cancer? Clin Oncol 2002; 14: 250-53.
81. Linde K, Hondras M, Vickers A, Riet Gt G, Melchart D. Systematic reviews of complementary therapies - an annotated bibliography. Part 3: Homeopathy. BMC Complement Altern Med 2001; 1: 4.
82. Dantas F, Rampes H. Do homeopathic medicines provoke adverse effects? A systematic review. Br Homeopath J 2000; 89: S35-38.
83. Kirby BJ. Safety of homeopathic products. J R Soc Med 2002; 95: 221-22.
84. Fisher P, Dantas F, Rampes H. The safety of homeopathic products. J R Soc Med 2002; 95: 474-75.
85. Thompson E, Barron S, Spence D. A preliminary audit investigating remedy reactions including adverse events in routine homeopathic practice. Homeopathy 2004; 93: 203-209.
86. Chakraborti D, Mukjerjee SC, Saha KC, Chowdhury UK, Rahman MM, Sengupta MK. Arsenic toxicity from homeopathic treatment. J Toxicol Clin Toxicol 2003; 41: 963-67.
87. Stevens WJ. Thallium intoxication caused by a homeopathic preparation. Toxicol Eur Res 1978; 1: 317-20.
88. Potier JP. Bromate intoxication due to the ingestion of a dose prescribed by a homeopathist. Nephrol Dial Transplant 1998; 13: 2978-79.
89. Kuenzli S, Grimaitre M, Krisher J, Saurat JH, Calza AM, Borradori L. Childhood Bullous pemphigoid: report of a case with life-threatening course during homeopathy treatment. Pediatr Dermatol 2004; 21: 160-63.
90. Mortelmans LJ, Biesemans L, Van Rossom P. Homeopathic products, not as innocent and safe as they seem? A case report. Eur J Emerg Med 2004; 11: 242-43.
91. Cardinali C, Francalanci S, Giomi B, Caproni M, Sertoli A, Fabbri P. Systemic contact dermatitis from herbal and homeopathic preparations used for herpes virus treatment. Acta Derm Venereol 2004; 84: 223-26.
92. Aberer W, Strohal R. Homeopathic preparations - severe adverse effects, unproven benefits. Dermatologica 1991; 182: 253.
93. De Smet PAGM. The role of plant-derived drugs and herbal medicines in health care. Drugs 1997; 54: 801-40.
94. Barnes J, Anderson LA, Phillipson JD. Herbal medicines, second edition. London: Pharmaceutical Press, 2002.
95. De Smet PAGM. Overview of herbal quality control. Drug Inf J 1998; 32: 717-24.
96. Bauer R. Quality criteria and standardisation of phytopharmaceuticals. Can acceptable drug standards be achieved? Drug Inf J, 1998; 32: 101-10.
97. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J 2000; 34: 15-23.
98. Scholten WK. Working with regulations in foreign countries with emphasis on good manufacturing practice for herbal medicines. Drug Inf J 2002; 36: 51-55.
99. Heigl D, Franz, G. Stability testing on typical flavonoid containing herbal drugs. Pharmazie 2003; 58: 881-85.
100. Chua KJ, Mujumdar AS, Chou SK. Intermittent drying of bioproducts - an overview. Bioresour Technol 2003; 90: 285-95.
101. Bedi MK, Shenefelt PD. Herbal therapy in dermatology. Arch Dermatol 2002; 138: 232-42.
102. Loew D, Kaszkin, M. Approaching the problem of bioequivalence of herbal medicinal products. Phyt-other Res 2002; 16: 705-11.
103. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003; 52: 1361-71.
104. Garrard J, Harms S, Eberly LE, Matiak A. Variations in product choice of frequently purchased herbs: caveat emptor. Arch Intern Med 2003; 163: 2290-95.
105. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety. Br J Clin Pharmacol 2003; 55: 331-40.
106. Ang HH, Lee KL, Kiyoshi M. Determination of lead in Smilax myosotiflora herbal preparation obtained in Malaysia. Int J Environ Health Res 2004; 14: 261-72.
107. Ernst E. The risk benefit profile of commonly used herbal therapies: Ginkgo, St John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136: 42-53.
108. Lingaerde O, Føreland AR, Magnusson A. Can winter depression be prevented by Ginkgo biloba extract? A placebo-controlled trial. Acta Psychiatr Scand 1999; 100: 62-66.
109. McKenna DJ, Jones K, Hughes H. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001; 7: 70-90.
110. Ernst E. Herbal medications for common ailments in the elderly. Drugs Aging 1999; 15: 423-28.
111. Le Bars PL, Kastelan J. Efficacy and safety of Ginkgo biloba extract. Public Health Nutr 2000; 3: 495-99.
112. LaFrance WC, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, Royall DR, Aylward E, Rumnans TA, Lovell MR. The use of herbal alternative medicines in neuropsychiatry. J Neuropsychiatry Clin Neurosci 2000; 12: 177-92.
113. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomised trials. Am J Med 2000; 108: 276-81.
114. Ritch R. Potential role for Ginkgo biloba extract in the treatment of glaucoma. Med Hypotheses 2000; 54: 216-20.
115. Loew D. The importance of Ginkgo biloba extracts in the therapy of Alzheimer dementia. Wien Med Wochenschr 2002; 152: 418-22.
116. Glisson J, Crawford R, Street S. The clinical applications of Ginkgo biloba, St John's Wort, Saw Palmetto, and soy. Nurse Pract 1999; 24: 28-49.
117. Wicor MZ. Ginkgo biloba for dementia: A reasonable alternative? J Am Pharm Assoc 1999; 39: 415-16.
118. Weiss R, Fintelmann V. Herbal medicine, second edition. New York: Thieme, 2000.
119. Behnke K, Jensen GS, Graubaum H-J, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Phytother Res 2001; 15: 549-51.
120. Vitiello B. Hypericum perforatum extracts as potential antidepressants. J Pharm Pharmacol 1999; 51: 513-17.
121. Evans MF, Morgenstern K. St John's wort: an herbal remedy for depression? Can Fam Physician 1997; 43: 1735-36.
122. Di Carlo G, Borrelli F, Ernst E, Izzo AA. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 2001; 22: 292-97.
123. Waddell DL, Hummel ME, Sumners AD. Three herbs you should get to know. Am J Nurs 2001; 101: 48-53.
124. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine 2003; 10: 66-86.
125. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3: 285-91.
126. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002; 12: 15-18.
127. Onega T. Saw palmetto for BPH: a review of a meta-analysis. J Am Acad Physicians Assistants 2002; 15: 59-65.
128. Anon. Is saw palmetto good for the prostate? Harvard Health Lett 1998; 23: 6.
129. Gerber GS. The physician's perspective. Health News 1998; 4: 1-2.
130. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol 2002; 19: 426-35.
131. Dennehy C. Botanicals in cardiovascular health. Clin Obstetr Gynecol 2001; 44: 814-23.
132. Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease. Arch Intern Med 1998; 158: 2225-34.
133. Blesken R. Crataegus in cardiology. Fortschr Med 1992; 110: 290-92.
134. Campbell FA, Tramer MR, Carioll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. Br Med J 2001; 323: 13-16.
135. Russo EB. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther 2001; 1: 21-92.
136. Vermani K, Garg S. Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol 2002; 80: 49-66.
137. Cohen MR. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in Hepatitis C virus. Clin Liver Dis 2001; 5: 461-78.
138. Ernst E, White AR. The BBC survey of complementary medicines use in the UK. Complement Ther Med 2000; 8: 32-36.
139. Spake A. Natural hazards. Tonic or toxic? US World News Rep 2001; 130: 42-49.
140. Kistorp TH, Laursen SB. Herbal medicines - evidence and drug interactions in clinical practice. Ugeskr Læger 2002; 164: 4161-65.
141. De Smet PAGM. Herbal remedies. N Engl J Med 2002; 347: 2046-56.
142. Wynn RL. Herbal remedies. Concerns from the medical community. Gen Dent 2002; 50: 14-20.
143. Hepner DL, Harnett MJP, Segal S, Camann W, Bader AM, Tsen LC. Herbal medicines during pregnancy: are they safe? Br J Obstetr Gynaecol 2002; 109: 1425-26.
144. Hepner DL, Harnett M, Segal S, Camann W, Bader AM, Tsen LC. Herbal medicine use in parturients. Anesthes Analges 2002; 94: 690-93
145. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246-52.
146. Pribitkin ED, Boger G. Herbal therapy. What every facial plastic surgeon must know. Arch Facial Plast Surg 2001; 3: 127-32.
147. Yoon S-J. Nearly half of all women 65 and older use herbal products to feel better, but don't tell their doctors. Florida Nurse 2001; 49: 27.
148. Butterweck V, Derendorf H, Gaus W, Nahrenstedt A, Schulz V, Unger M. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004; 70: 784-91.
149. Wong AL, Chan JT, Chan TY. Adverse herbal interactions causing hypotension. Ther Drug Monit 2003; 25: 297-98.
150. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis 2004; 44: 1-11.
151. Schneider C, Bord C, Misse B, Arnaud B, Schmitt-Bernard C-F. Spontaneous hyphema caused by Ginkgo biloba extract. J Fr Ophtalmol 2002; 25: 731-32.
152. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001; 30: 523-25.
153. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775-76.
154. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933.
155. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336: 1108.
156. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998; 352: 36.
157. Hodges PJ, Kam PCA. The peri-operative implications of herbal medicines. Anaesthesia 2002; 57: 889-99.
158. Assemi M. Herbs affecting the nervous system: Ginkgo, Kava, St John's wort, and valerian. Clin Obstetr Gynecol 2001; 44: 824-35.
159. Cianfrocca C, Pellicia F, Auriti A, Santini M. Ginkgo biloba-induced ventricular arrhythmia. Ital Heart J 2002; 3: 689-91.
160. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136: 42-53.
161. Witowski JA, Parish LC. Dermatologic manifestations of complementary therapy. SKINmed 2003; 2: 175-80.
162. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999; 59: 1239-44.
163. Kiken DA, Cohen DE. Contact dermatitis to botanical extracts. Am J Contact Dermatitis 2002; 13: 148-52.
164. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible increase in photosensitivity to UB-B caused by St John's wort extract. Hautarzt 1997; 47: 249-52.
165. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16: 359-67.
166. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89-94.
167. Pies R. Adverse neuropsychiatric reactions to herbal and over-the-counter 'anti-depressants'. J Clin Psychiatry 2000; 61: 815-20.
168. Haller C, Borowitz N. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833-38.
169. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999; 37: 485-89.
170. Anon. Herbal stimulant causes US deaths. Br Med J 1996; 312: 1378-79.
171. Ernst E, Pittler MH. Risks associated with herbal medicinal products. Wien Med Wochenschr 2002; 152: 183-89.
172. Kaberi-Oterod J, Conetta R, Kundo KK, Farkash A. Ischemic stroke in a user of thermodrene: a case study in alternative medicine. Clin Pharmacol Ther 2002; 72: 343-46.
173. Schulman S. Addressing the potential risks associated with Ephedra use: a review of recent efforts. Pub Health Rep 2003; 118: 487-92.
174. Abourashed EA, El-lfy AT, Khan IA, Walker L. Ephedra in perspective - a current review. Phytother Res 2003; 17: 702-12.
175. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-58.
176. Ryan, CK, Reamy B, Rochester JA. Ischemic colitis associated with herbal product use in young women. J Am Board Fam Pract 2002; 15: 309-12.
177. Ernst E. Cardiovascular adverse effects of herbal medicines: a systematic review of the recent literature. Can J Cardiol 2003; 19: 818-27.
178. Chen C, Biller J, Willing SJ, Lopez AM. Ischemic stroke after using over the counter products containing ephedra. J Neurol Sci 2004; 217: 55-60.
179. Gyllenhaal C, Merritt SL, Peterson SD, Block KI, Gochenour T. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev 2000; 4: 229-51.
180. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31: 89-97.
181. Russman S, Lauterburg BH, Helbing A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69.
182. Pepping J. Kava: Piper methysticum. Am J Health Syst Pharm 1999; 56: 957-60.
183. Haller CA, Anderson IB, Kim SY, Blanc PD. An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events. Adv Drug React Toxicol Rev 2002; 21: 143-50.
184. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003; 41: 821-29.
185. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including hepatotoxicity. Phytomedicine 2003; 10: 440-46.
186. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003; 41: 109-13.
187. Moulds RF, Malani J. Kava: herbal panacea or liver poison? Med J Aust 2003; 178: 451-53.
188. Brauer RB, Stangl M, Stewart JR, Pfab B, Becker K. Acute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum). J Clin Psychiatry 2003; 64: 216-18.
189. Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust 2003; 178: 421-22.
190. Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie J. Saccade and cognitive function in chronic kava users. Neuropsychopharmacology 2003; 28: 389-96.
191. Mullins RJ. Echinacea-associated anaphylaxis. Med J Aust 1998; 168: 170-71.
192. Mullins RJ. Adverse reactions associated with Echinacea: the Australian experience. Ann Allergy Asthma Immunol 2002; 88: 42-51.
193. Kligler B. Echinacea. Am Fam Physician 2003; 67: 77-80.
194. Shaw D, Christine L, Stokyo K, Murray V. Traditional remedies and food supplements. A 5-year toxicological review (1991-95). Drug Saf 1997; 17: 342-56.
195. Bagheri H, Broué P, Lacroix I, Larrey D, Olives JP, Vayasse PH, Ghisolfi J, Montastruc JL. Fulminant hepatic failure after herbal medicine ingestion in children. Thérapie 1998; 53: 77-83.
196. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67: 1755-58.
197. Philp RB. Herbal drug interactions and adverse effects. An evidence based quick reference guide. London: McGraw-Hill, 2004.
198. Edmonds SEF, Montgomery JC. Reversible ovarian failure induced by a Chinese herbal medicine: lei gong teng. Br J Obstetr Gynaecol 2003; 110: 77-78.
199. Moore N, Biour M, Paux G, Loupi E, Begaud B, Bolsmare F. Adverse drug reaction monitoring; doing it the French way. Lancet 1985; ii: 1056-58.
200. Larry D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander [Teucrium chaemaedrys] administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-32.
201. Eriksson JW, Carlberg B, Hillbörn V. Life threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med 1999; 245: 307-10.
202. Elinav E, Chajek-Shaul T. Licorice consumption causing severe hypokalaemic paralysis. Mayo Clin Proc 2003; 78: 767-68.
203. Costello C. Estrogenic substances from plants. J Am Pharm Assoc 1950; 39: 177-80.
204. Holt S. Phytoestrogens for a healthier menopause. Altern Ther Health Med 1997; 1: 187-93.
205. Brinker F. Herb contraindications and drug interactions, third edition. Sandy, OR: Eclectic Medical Publications, 2001.
206. Carlson C. Herbs and hepatitis. Lancet 1990; 336: 1068.
207. Bensoussan A, Myers SP, Carlton A-L. Risks associated with the practice of traditional Chinese medicine. Arch Fam Med 2000; 9: 1071-78.
208. Chan TYK. The prevalence, use and harmful potential of some Chinese herbal medicines in babies and children. Vet Hum Toxicol 1994; 36: 238-40.
209. Chan TYK, Chan AYW, Critchley JAJH. Hospital admissions due to adverse reactions to Chinese herbal medicines. J Trop Med Hyg 1992; 95: 296-98.
210. Niggemann B, Grüber C. Side-effects of complementary and alternative medicine. Allergy 2003; 58: 707-16.
211. Wang XP, Yang RM. Movement disorders possibly induced by traditional Chinese herbs. Eur Neurol 2003; 50: 153-59.
212. Hohman N, Koffler K. Letter to the editor. Int J Environ Health Res 2002; 12: 99-100.
213. Argento A, Tiraferri E, Marzaloni M. Oral anticoagulants and medicinal plants. An emerging interaction. Ann Ital Med Intern 2000; 15: 139-43.
214. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000; 143: 923-29.
215. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003; 18: 451-71.
216. Fogden E, Neuberger J. Alternative medicines and the liver. Liver Int 2003; 23: 213-20.
217. Stout CW, Weinstock J, Homoud MK, Wang PJ, Estes M, Link MS. Herbal medicine: beneficial effects, side effects, and promising new research in the treatment of arrhythmias. Curr Cardiol Rep 2003; 5: 395-401.
218. Schiano TD. Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 2003; 7: 453-73.
219. Saxena AK, Panhotra BR. Herbal remedies: renal tragedies. Swiss Med Wkly 2003; 133: 188-89.
220. Dykeman-Sharpe J. Over-the-counter remedies in chronic renal insufficiency: risks versus benefits. Can Assoc Nephrol Nurses Technicians J 2003; April-June: 17-28.
221. Vender RB. Adverse reactions to herbal therapy in dermatology. Skin Ther Lett 2003; 8: 5-8.
222. Huang S-M, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. Drug interactions with herbal products and grapefruit juice. A conference report. Clin Pharmacol Ther 2004; 75: 1-12.
223. Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines - a systematic review. Acta Psychiatr Scand 2003; 108: 83-91.
224. Rousseaux CG, Schacter H. Regulatory issues concerning the safety, efficacy and quality of herbal medicines. Birth Defects Res 2003; 68: 505-10.
225. Tiran D. The use of herbs by pregnant women and childbearing women: a risk-benefit assessment. Complement Ther Nurs Midwif 2003; 9: 176-81.
226. Buttar HS, Jones KL. What do we know about the reproductive and developmental risks of herbal and alternate remedies? Birth Defects Res 2003; 68: 492-93.
227. Jurgens TM. Potential toxicities of herbal remedies in the developing fetus. Birth Defects Res 2003; 68: 496-98.
228. Gallo M, Einarson A, Koren G. Herbal medicine use in pregnancy: a new frontier in clinical toxicology. Birth Defects Res 2003; 68: 499-500.
229. Johns T, Sibeko L. Pregnancy outcomes in women using herbal therapies. Birth Defects Res 2003; 68: 501-504.
230. Conover EA. Herbal agents and over-the-counter medications in pregnancy. Clin Endocrinol Metab 2003; 17: 237-51.
231. Ciganda C, Laborde A. Herbal infusions used for abortion. J Toxicol Clin Toxicol 2003; 41: 235-39.
232. Woolf AD. Herbal remedies and children: do they work? Are they harmful? Pediatrics 2003; 112: 240-45.
233. Ernst E. Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence. Eur J Pediatr 2003; 162: 72-80.
234. Buehler BA. Interactions of herbal products with conventional medicines and potential impact on pregnancy. Birth Defects Res 2003; 68: 494-95.
235. Frieri M. Herbal therapies: what allergist-immunologists should know regarding patient use of complementary and alternative medicine. Allerg Asthma Proc 2001; 22: 209-15.
236. Huxtable RJ. The harmful potential of herbal and other plant products. Drug Saf 1990; 5: 126-36.
237. Knoblauch A, Schafroth U, Paky A, Galeazzi RL. Amborum special F and ASFO: two glucocorticoid containing herbal remedies. Schweiz Med Wochenschr 1989; 119: 796-802.
238. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002; 23: 136-39.
239. Auyeung TW, Chang KKF, To CH, Mak A, Szeto ML. Three patents with lead poisoning following use of a Chinese herbal pill. Hong Kong Med J 2002; 8: 60-62.
240. Lee A-Y, Eun H-C, Kim H-O, Moon K-C, Lee C-H, Kim G-J, Kim S-C, Ham J-H. Multicenter study of the frequency of contact allergy to gold. Contact Dermatitis 2001; 45: 214-16.
241. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD. Herb-drug interactions: an evidence based approach. Curr Med Chem 2004; 11: 1513-25.
242. Evans V. Herbs and the brain: friend or foe? The effects of Ginkgo and garlic on warfarin use. J Neurosci Nurs 2000; 32: 229-32.
243. Smith L, Ernst E, Ewings P, Myers P, Smith M. Co-ingestions of herbal medicines and warfarin. Br J Gen Pract 2004; 54: 439-41.
244. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforation): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56.
245. Yue QY, Bergquist C, Gerden B. Safety of St John's wort. Lancet 2000; 355: 576-77.
246. Neuman M. Metabolic effects and drug interactions provoked by certain substances of plant origin: grapefruit, St John's wort and garlic. Presse Med 2002; 31: 1416-22.
247. Iten F, Reichling J, Sailer R. Side effects and interactions of phytopharmaceuticals. Ther Umschau 2002; 59: 283-91.
248. Hall SD, Wang Z, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 525-35.
249. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500-504.
250. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98.
251. Izzo A. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42: 139-48.
252. Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 2004; 25: 129-36.
253. Zhou S, Koh H-L, Gao Y, Gong Z-y, Lee EJD. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004; 74: 935-68.
254. Thompson Coon J, Pittler M, Ernst E. Herb-drug interactions: survey of leading pharmaceutical companies. Arch Intern Med 2003; 163: 1371.
255. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-38.
256. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-95.
257. Boyle FM. Adverse interaction of herbal medicine wit breast cancer treatment. Med J Aust 1997; 167: 286.
258. Gold JL, Laxer DA, Dergal JM, Lanctôt L, Rochon PA. Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 2001; 4: 29-34.
259. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharmacol Ther 2002; 27: 391-401.
260. Harada T, Ohtaki E, Misu K, Sumiyoshi T, Hosoda S. Congestive heart failure caused by digitalis toxicity in an elderly man taking a licorice-containing Chinese herbal laxative. Cardiology 2002; 98: 218.
261. Light TD, Light, JA. Acute renal transplantation rejection possibly related to herbal medications. Am J Transplant 2003; 3: 1608-609.
262. Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10: 163-69.
263. Awang DVC, Fugh-Berman A. Herbal interactions with cardiovascular drugs. J Cardiovasc Nurs 2002; 16: 64-70.
264. Lis-Balchin M. Serious adverse effects between herbal remedies and conventional drugs taken simultaneously. J R Soc Promotion Health 2002; 122: 210.
265. Tyagi A, Delanty N. Herbal remedies, dietary supplements, and seizures. Epilepsia 2003; 44: 228-35.
266. Cheng KF, Leung KS, Leung PC. Interactions between modern and Chinese medicinal drugs: a general review. Am J Chin Med 2003; 31: 163-69.
267. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf 2003; 26: 1075-92.
268. Clark A. Finding health in folklore, herbs and supplements: the good, the bad and the ugly. Missouri Med 2003; 100: 91-93.
269. Miller LG. Herbal medicinals: selected clinical considerations focussing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200-11.
270. But PP-H. Need for correct identification of herbs in herbal poisoning. Lancet 1993; 341: 637.
271. Lu Y. Herb use in critical care. What to watch for. Crit Care Nurs Clin N Am 2003; 15: 313-19.
272. Loew D, Kaszkin M. Approaching the problem of bioequivalence of herbal medicinal products. Phytother Res 2002; 16: 705-11.
273. Straus SE. Herbal medicines - what's in the bottle? N Engl J Med 2002; 347: 1997-98.
274. Castot A, Djezzar S, Delau N, Guillot B, Efthymiou ML. Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants. Thérapie 1997; 52: 97-103.
275. De Smet PAGM, Brouwers RBJ. Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32: 427-36.
276. Marcus DM, Grollman AP. Botanical medicines - the need for new regulations. N Engl J Med 2002; 347: 2073-76.
277. Drew AK, Myers SP. Safety issues in herbal medicine: implications for the health professions. Med J Aust 1997; 19: 538-41.
278. Angell M, Kassirer JP. Alternative medicines - the risks of untested and unregulated remedies. N Engl J Med 1998; 339: 839-41.
279. De Smet P. Should herbal medicine-like products be licensed as medicines. Br Med J 1995; 310: 1023-24.
280. Ashcroft DM, Po ALW. Herbal remedies. Issues in licensing and economic evaluation. Pharmacoeconomics 1999; 16: 321-28.
281. Stein K. Herbal supplements and prescription drugs. A risky combination? J Am Dietetic Assoc 2000; 100, 412.
282. Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicines background. Toxicology 2002; 181-182: 103-107.
283. World Health Organization. Regulatory situation of herbal medicines. WHO, 1998, WHO/TRM/98.1.
284. Briggs DR. The regulation of herbal medicines in Australia. Toxicology 2002; 181-182: 565-70.
285. Wohlmuth H, Oliver C, Mathan PJ. A review of the status of Western herbal medicine in Australia. J Herbal Pharmacother 2002; 2: 33-46.
286. Anon. Reminder: St John's Wort (Hypericum perforatum) interactions. Curr Problems 2000; 26: 6-7.
287. Anon. Psoralea corylifolia fruit in traditional Chinese Medicines causing severe skin reactions. Curr Problems 2001; 27: 12-13.
288. Anon. 2002. Retrieved from: http://www.mca.gov.uk. Last accessed 13 March 2005.
289. Anon, Agency bans the use of kava kava in foods. 2002. Retrieved from: http://www.food.gov.uk. Last accessed 5 January 2005.
290. Anon. Review of herbal ingredients for use in unlicensed herbal medicinal products. Medicines Control Agency, 2001. Retrieved from: http:// www.mca.gov.uk. Last accessed 13 March 2005.
291. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-85.
292. Rousseaux CG, Schacter H. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Res 2003; 68: 505-10.
293. Silano M, De Vincenzi M, De Vincenzi A, Silano V. The new European legislation on traditional herbal medicines: main features and perspectives. Fitoterapia 2004; 75: 107-16.
294. Angell M, Kassirer JP. Alternative medicines - the risks of untested and unregulated medicines. N Engl J Med 1998; 339: 839-41.
295. Marcus DM, Grollam AP. Botanical medicines - the need for new regulations. N Engl J Med 2002; 347: 2073-76.
296. Anon. Current Good Manufacturing Practice in manufacturing, packing, or holding dietary ingredients and dietary supplements; Proposed Rule. Federal Register 2003; March 13, 21 CFR Parts 111 and 112.
297. Spoerke DG. Toxicity of homeopathic products. Vet Hum Toxicol 1989; 31: 25-26.
298. Dasgupta A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. Am J Clin Pathol 2003; 120: 127-37.
299. Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem 2003; 40: 489-507.
300. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34: 352-58.
301. Barnes J. Pharmacovigilance of herbal medicines. A UK perspective. Drug Saf 2003; 26: 829-51.
302. Peters D, Hom MF, Donaldson J, Chausselet T, Toffa S, Whitehouse J, Carroll D, Barry P. Time for a new approach for reporting herbal medicine adverse effects. J Altern Complement Med 2003; 9: 607-609.
303. Chan TKY. Monitoring the safety of herbal medicines. Drug Saf 1997; 17: 209-15.
304. Barnes J, Mills SY, Abbott NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal products and conventional OTC medicines: face-to face interviews with 515 users of herbal medicines. Br J Clin Pharmacol 1998; 45: 496-500.
305. Pal SK, Shukla Y. Herbal medicine: current status and the future. Asian Pacific J Cancer Prevention 2003; 4: 281-88.
306. Ness J, Nisly N. Tolyherbacy': herbal supplements as a form of polypharmacy in older adults. J Gerontol 2003; 58A: 478.
307. Smith L, Ernst E, Ewings P, Myers P. Co-ingestion of herbal medicines and warfarin. Br J Gen Pract 2004; 54: 439-41.
308. Walker LA, Budd S. UK: the current state of regulation of complementary and alternative medicine. Complement Ther Med 2002; 10: 8-13.
309. Barnes J. Meeting the impact of the traditional herbal medicinal products directive. Conference organised by the British Institute of Regulatory Affairs, London, January, 2003. Complement Ther Med 2003; 11: 129-30.
310. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol 2002; 55: 226-33.